



## Subset list of prescription drugs and insulin products for affordability reviews

Table 1 Prescription drug subset list for June 17, 2026, PDAB review

Key: ^Indicates a drug reviewed in 2025

Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives ( <i>non-proprietary name</i> )
Jardiance <sup>^</sup>	<i>empagliflozin</i>	Antidiabetics	Treats Type 2 diabetes, heart failure, and chronic kidney disease.	<ul style="list-style-type: none"> <li>- Brenzavvy (<i>bexagliflozin</i>)</li> <li>- Farxiga (<i>dapagliflozin</i>)</li> <li>- Invokana (<i>canagliflozin</i>)</li> <li>- Steglatro (<i>ertugliflozin</i>)</li> </ul>
Mounjaro <sup>^</sup>	<i>tirzepatide</i>	Antidiabetics	Improves blood sugar control in adults with type 2 diabetes.	<ul style="list-style-type: none"> <li>- Byetta (<i>exenatide synthetic</i>)</li> <li>- Ozempic (<i>semaglutide</i>)</li> <li>- Rybelsus (<i>semaglutide</i>)</li> <li>- Trulicity (<i>dulaglutide</i>)</li> <li>- Victoza (<i>liraglutide</i>)</li> </ul>
Ozempic <sup>^</sup>	<i>semaglutide</i>	Antidiabetics	Improves blood sugar control and lowers the risk of major cardiovascular events in adults with type 2 diabetes.	<ul style="list-style-type: none"> <li>- Byetta (<i>exenatide synthetic</i>)</li> <li>- Mounjaro (<i>trzepatide</i>)</li> <li>- Rybelsus (<i>semaglutide</i>)</li> <li>- Trulicity (<i>dulaglutide</i>)</li> <li>- Victoza (<i>liraglutide</i>)</li> </ul>



Table 2 Insulin subset list for June 17, 2026, PDAB review

Proprietary name(s)	Non-proprietary name	Therapeutic class	Insulin subclass	NDC	Main conditions treated
<b>Humulin R U-500 (Concentrated)</b>	<i>Insulin regular</i>	Human insulin	Short acting insulin	00002882427	Improve blood sugar control in adults and children with diabetes (Type-1 and Type 2) who require more than 200 units of insulin per day.
<b>Humulin R U-500 KwikPen</b>	<i>Insulin regular</i>	Human insulin	Short acting insulin	00002850101	Improve blood sugar control in adults and children with diabetes (Type-1 and Type 2) who require more than 200 units of insulin per day.

Table 3 Prescription drug subset list for July 15, 2026, PDAB review

\*Indicates a drug with a designated orphan condition

Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives ( <i>non-proprietary name</i> )
<b>Keytruda*</b>	<i>pembrolizumab</i>	Antineoplastics and adjunctive therapies	Treats many types of cancers: Skin, lung, blood, bladder, gastrointestinal, gynecologic, and breast. <b>Orphan conditions:</b> Treats rare melanoma, classic Hodgkin Lymphoma; primary mediastinal large B-cell lymphoma; small cell lung cancer.	<ul style="list-style-type: none"> <li>- Bavencio (<i>avelumab</i>)</li> <li>- Imfinzi (<i>durvalumab</i>)</li> <li>- Jemperli (<i>dostarlimab-gxly</i>)</li> <li>- Libtayo (<i>cempimab-rwlc</i>)</li> <li>- Opdivo (<i>nivolumab</i>)</li> <li>- Tecentriq (<i>atezolizumab</i>)</li> </ul>



Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives ( <i>non-proprietary name</i> )
<b>Verzenio</b>	<i>abemaciclib</i>	Antineoplastics and adjunctive therapies	Treatment of hormone receptor–positive (HR+), HER2-negative breast cancer in adults across both early-stage and advanced disease.	<ul style="list-style-type: none"> <li>- Ibrance (<i>palbociclib</i>)</li> <li>- Kisqali (<i>ribociclib succinate</i>)</li> </ul>
<b>Xeljanz</b>	<i>tofacitinib citrate</i>	Analgesics - anti-inflammatory	Treats several autoimmune and inflammatory conditions in adults and children: Rheumatoid arthritis (RA) – Adults; Psoriatic arthritis (PsA) – Adults; Ankylosing spondylitis (AS) – Adults; Ulcerative colitis (UC) – Adults; Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA) – Pediatric (≥2 years).	<ul style="list-style-type: none"> <li>- Enbrel (<i>etanercept</i>)</li> <li>- Humira (<i>adalimumab</i>)</li> <li>- Olumiant (<i>baricitinib</i>)</li> <li>- Remicade (<i>infliximab</i>)</li> <li>- Rinvoq (<i>upadacitinib</i>)</li> <li>- Simponi (<i>golimumab</i>)</li> </ul>

Table 4 Prescription drug subset list for August 19, 2026, PDAB review

\*Indicates a drug with a designated orphan condition

Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives ( <i>non-proprietary name</i> )
<b>Ocrevus</b>	<i>ocrelizumab</i>	Immuno-modulatory agent	Treats relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults.	<ul style="list-style-type: none"> <li>- Briumvi (<i>ublituximab-xiiy</i>)</li> <li>- Kesimpta (<i>ofatumumab</i>)</li> <li>- Lemtrada (<i>alemtuzumab</i>)</li> <li>- Rituxan (<i>rituximab</i>)</li> <li>- Tysabri (<i>natalizumab</i>)</li> </ul>



Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives ( <i>non-proprietary name</i> )
<b>Skyrizi*</b>	<i>risankizumab-rzaa</i>	Dermatologicals	<p>Immune-mediated inflammatory conditions: Moderate-to-severe plaque psoriasis; active psoriatic arthritis; moderately to severely active Crohn’s disease; and moderately to severely active ulcerative colitis.</p> <p><b>Orphan condition:</b> Treatment of pediatric Crohn's disease.</p>	<ul style="list-style-type: none"> <li>- Bimzelx (<i>bimekizumab-bkzx</i>)</li> <li>- Cosentyx (<i>secukinumab</i>)</li> <li>- Enbrel (<i>etanercept</i>)</li> <li>- Envyio (<i>vedolizumab</i>)</li> <li>- Humira (<i>adalimumab</i>)</li> <li>- Ilumya (<i>tildrakizumab-asmn</i>)</li> <li>- Omvoh (<i>mirikizumab-mrkz</i>)</li> <li>- Remicade (<i>infliximab</i>)</li> <li>- Stelara (<i>ustekinumab</i>)</li> <li>- Taltz (<i>ixekizumab</i>)</li> <li>- Tremfya (<i>guselkumab</i>)</li> </ul>
<b>Tremfya</b>	<i>guselkumab</i>	Dermatologicals	<p>Treats immune-mediated inflammatory conditions: moderate-to-severe plaque psoriasis; active psoriatic arthritis; and moderately to severely active ulcerative colitis.</p>	<ul style="list-style-type: none"> <li>- Bimzelx (<i>bimekizumab-bkzx</i>)</li> <li>- Cosentyx (<i>secukinumab</i>)</li> <li>- Enbrel (<i>etanercept</i>)</li> <li>- Envyio (<i>vedolizumab</i>)</li> <li>- Humira (<i>adalimumab</i>)</li> <li>- Ilumya (<i>tildrakizumab-asmn</i>)</li> <li>- Omvoh (<i>mirikizumab-mrkz</i>)</li> <li>- Remicade (<i>infliximab</i>)</li> <li>- Skyrizi (<i>risankizumab-rzaa</i>)</li> <li>- Stelara (<i>ustekinumab</i>)</li> <li>- Taltz (<i>ixekizumab</i>)</li> </ul>



Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives ( <i>non-proprietary name</i> )
<b>Xolair</b>	<i>omalizumab</i>	Antiasthmatic and bronchodilator agents	Treats allergic and inflammatory conditions in both adults and children: Moderate to severe persistent asthma; chronic rhinosinusitis with nasal polyps (CRSwNP); IgE-mediated food allergy; and chronic spontaneous urticaria (CSU).	<ul style="list-style-type: none"><li>- Cinqair (<i>reslizumab</i>)</li><li>- Dupixent (<i>dupilumab</i>)</li><li>- Fasenra (<i>benralizumab</i>)</li><li>- Nucala (<i>mepolizumab</i>)</li><li>- Tezspire (<i>tezepelumab-ekko</i>)</li></ul>

**Sept. 16 and Oct. 21:** The board will review of all drugs and discuss recommendations for annual report.